Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The GHSR1a antagonist LEAP2 regulates islet hormone release in a sex-specific manner.
J Endocrinol
November 2024
School of Life and Health Sciences, University of Roehampton, London, UK.
LEAP2, a liver-derived antagonist for the ghrelin receptor, GHSR1a, counteracts the effects of ghrelin on appetite and energy balance. Less is known about its impact on blood glucose-regulating hormones from pancreatic islets. Here, we investigate whether acyl-ghrelin (AG) and LEAP2 regulate islet hormone release in a cell-type- and sex-specific manner.
View Article and Find Full Text PDFGLP-1R mediates idebenone-reduced blood glucose in mice.
Biomed Pharmacother
September 2024
Department of Endocrinology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan, Shanxi 030001, China. Electronic address:
GLP-1 receptor agonists (GLP-1RAs) are an innovative class of drugs with significant therapeutic value for type 2 diabetes mellitus (T2DM). The GLP-1RAs currently available on the market are biologic macromolecular peptide agents that are expensive to treat and not easy to take orally. Therefore, the development of small molecule GLP-1RAs is becoming one of the most sought-after research targets for hypoglycemic drugs.
View Article and Find Full Text PDFShould we routinely assess hypothalamic-pituitary-adrenal axis in pediatric patients with Prader-Willi syndrome?
Front Endocrinol (Lausanne)
July 2024
Department of Pediatric and Adolescent Endocrinology, Jagiellonian University Medical College, Kraków, Lesser Poland, Poland.
Background: It has been reported that central adrenal insufficiency (CAI) in pediatric patients (pts) with Prader-Willi syndrome (PWS) may be a potential cause of their sudden death. In addition, the risk of CAI may increase during treatment with recombinant human growth hormone (rhGH).
Objective: To prevent both over- and undertreatment with hydrocortisone, we evaluated the prevalence of CAI in a large multicenter cohort of pediatric pts with PWS analyzing adrenal response in the low-dose ACTH test (LDAT) and/or the glucagon stimulation test (GST) and reviewing the literature.
Inadequate Glucagon Suppression During OGTT in Prediabetes: A Systematic Review and Meta-analysis.
J Clin Endocrinol Metab
September 2024
Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin 300052, China.
Context: Glucagon plays a role in the development of type 2 diabetes, yet its role in prediabetes (preDM) remains uncertain.
Objective: To evaluate glucagon levels in the fasting state and its response to glucose inhibition in preDM through meta-analysis.
Methods: A systematic search across Pubmed, Embase, Web of Science, and Cochrane Library identified studies assessing glucagon levels during 75 g oral glucose tolerance test (OGTT) in both preDM and normal glucose tolerance (NGT) cohorts.
Preanalytical impact on the accuracy of measurements of glucagon, GLP-1 and GIP in clinical trials.
Scand J Clin Lab Invest
December 2023
Department of Clinical Biochemistry, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark.
Article Synopsis
- The study examined how different blood containers affect the measurement of hormones like glucagon, GLP-1, and GIP during metabolic research.
- It involved overweight participants who were tested under controlled conditions using various blood sample containers.
- Results showed that while glucagon levels were consistent across containers, GLP-1 and GIP levels varied significantly based on the container used, suggesting specific containers are preferable for accurate hormone measurement in clinical trials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!